NRICHDX

Company Snapshot

Founded: 2016
Entity Type: Private
Region: U.S.
Headquarter: California, U.S.
Key Geographics: North America
Corporate Address: 15339 Barranca Parkway Irvine, California 92618 U.S. Tel. +1-833-674-2439 www.nrichdx.com

Company Overview

Founded in 2016 as WaveSense, nRichDX Inc. is developing and marketing semi-automated magnetic-based sample preparation products and services for capturing a range of liquid biopsy materials including cfDNA, ctDNA, exosomes, and CTCs.

The company’s sample preparation platform, called Revolution, is designed to provide high yields of material for analysis. The three components of the platform include the Revolution Processor, Revolution nRicher Cartridge and Revolution cfDNA Isolation kits. The platform also includes magnetic beads that are surface-coated to target and capture cfDNA.

The Revolution system can process large sample sizes (up to 50 ml), making it useful for early-stage detection applications. The technology addresses an outstanding industry need more accurate liquid biopsy diagnostic tests due to lack of target material.

The company is addressing the need to capture target material that is extremely rare, and rarer as one gets into lower level of frequencies and earlier stages of cancer. The platform is intended to address the efficiencies and recovery rates in the liquid biopsy sample preparation industry.

In April 2023, Agena Bioscience and nRichDX elevated their existing technical collaboration to a commercial partnership, jointly promoting their products to researchers engaged in the development of liquid biopsy applications on the Agena MassARRAY platform.

In September 2023, nRichDX has launched its new RUO-labeled CTC enrichment kit that uniquely isolates circulating tumor cells (CTCs) from up to 40mL of whole blood samples to help researchers advance liquid biopsy assay research and development.

NRICHDX In Reports

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Discover BCC Research's report on Next-generation Sequencing Market is steadily being integrated into clinical laboratory analysis, testing, and disease diagnostics in healthcare sectors globally.

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

BCC Research Market Report says clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a (CAGR) of 31.4%.

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

BCC Market Research Report for global liquid biopsy research tools, liquid biopsy biomarkers, technologies, services and diagnostics markets.

Company's Business Segments

  • Liquid Biopsy : Liquid Biopsy sample preparation Platform that can process volumes from 1 mL-50 mL and offers a single solution for multiple specimen types and targets.

Applications/End User Industries

  • Liquid Biopsy
  • Medical Device
  • Molecular Diagnostics
  • Cancer Diagnostics
  • Precision Medicine
AI Sentiment